vs
Side-by-side financial comparison of Celcuity Inc. (CELC) and Fortrea Holdings Inc. (FTRE). Click either name above to swap in a different company.
Celcuity Inc. is a clinical-stage biotechnology company specializing in oncology. It develops personalized cancer treatment solutions through its proprietary functional cell analysis technology, targeting unmet medical needs for patients with hard-to-treat solid tumors, with primary operations in the U.S. and partnerships across global biopharmaceutical networks.
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $660.5M | ||
| Q3 25 | — | $701.3M | ||
| Q2 25 | — | $710.3M | ||
| Q1 25 | — | $651.3M | ||
| Q4 24 | — | $697.0M | ||
| Q3 24 | — | $674.9M | ||
| Q2 24 | — | $662.4M | ||
| Q1 24 | — | $662.1M |
| Q4 25 | — | $-32.5M | ||
| Q3 25 | — | $-15.9M | ||
| Q2 25 | — | $-374.9M | ||
| Q1 25 | — | $-562.9M | ||
| Q4 24 | — | $-61.2M | ||
| Q3 24 | — | $-27.9M | ||
| Q2 24 | — | $-138.4M | ||
| Q1 24 | — | $-101.0M |
| Q4 25 | — | -2.1% | ||
| Q3 25 | — | -1.2% | ||
| Q2 25 | — | -46.5% | ||
| Q1 25 | — | -79.9% | ||
| Q4 24 | — | -8.0% | ||
| Q3 24 | — | -2.7% | ||
| Q2 24 | — | -7.7% | ||
| Q1 24 | — | -5.6% |
| Q4 25 | — | -4.9% | ||
| Q3 25 | — | -2.3% | ||
| Q2 25 | — | -52.8% | ||
| Q1 25 | — | -86.4% | ||
| Q4 24 | — | -8.8% | ||
| Q3 24 | — | -4.1% | ||
| Q2 24 | — | -20.9% | ||
| Q1 24 | — | -15.3% |
| Q4 25 | — | $-0.25 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | — | $-4.14 | ||
| Q1 25 | — | $-6.25 | ||
| Q4 24 | — | $-0.68 | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | — | $-1.55 | ||
| Q1 24 | — | $-1.13 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
